Biodexa Pharmaceuticals Plc
corporate_fare Company Profile
Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 37 items for BDRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-11, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 19 rated 8 or above. Recent SEC coverage for BDRX spans 424B3, 6-K, F-1/A, F-1.
Recent high-impact activity:
- Biodexa 1H26 Results: Going Concern Warning and Nasdaq Delisting Risk
- Biodexa's 1H26 Results Highlight Cash Runway to Q4 2026 and Going Concern Uncertainty
- Biodexa Flags Going Concern Risk as Cash Dwindles to £3.2M
- Biodexa Hits Major Milestone in Serenta Phase 3 FAP Trial
- Biodexa Shareholders Reverse Course, Approve 1-for-10,000 Reverse Split
Financial Snapshot
Dilution Risk
High riskFiling-implied dilution signals for BDRX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-11.
Multi-Part Offering Finalized · Discounted Pricing
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
BDRX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.